178 related articles for article (PubMed ID: 15270644)
21. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
[TBL] [Abstract][Full Text] [Related]
22. Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy.
Arlen PM; Gulley JL; Madan RA; Hodge JW; Schlom J
Crit Rev Immunol; 2007; 27(5):451-62. PubMed ID: 18197807
[TBL] [Abstract][Full Text] [Related]
23. Plasmid DNA and viral vector-based vaccines for the treatment of cancer.
Anderson RJ; Schneider J
Vaccine; 2007 Sep; 25 Suppl 2():B24-34. PubMed ID: 17698262
[TBL] [Abstract][Full Text] [Related]
24. Vaccine therapy for prostate cancer.
Sonpavde G; Spencer DM; Slawin KM
Urol Oncol; 2007; 25(6):451-9. PubMed ID: 18047951
[TBL] [Abstract][Full Text] [Related]
25. Dendritic cell vaccines in melanoma: from promise to proof?
Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
[TBL] [Abstract][Full Text] [Related]
26. Integrating bench with bedside: the role of vaccine therapy in the treatment of solid tumors.
Kaufman HL
J Clin Oncol; 2005 Feb; 23(4):659-61. PubMed ID: 15613694
[No Abstract] [Full Text] [Related]
27. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
Berinstein NL
Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
[TBL] [Abstract][Full Text] [Related]
28. CEA loaded dendritic cell vaccines.
Morse MA; Clay TM; Lyerly HK
Cancer Chemother Biol Response Modif; 2002; 20():385-90. PubMed ID: 12703216
[No Abstract] [Full Text] [Related]
29. Carcinoembryonic antigen-based vaccines.
Marshall J
Semin Oncol; 2003 Jun; 30(3 Suppl 8):30-6. PubMed ID: 12881810
[TBL] [Abstract][Full Text] [Related]
30. Multiple effector mechanisms induced by recombinant Listeria monocytogenes anticancer immunotherapeutics.
Wallecha A; Carroll KD; Maciag PC; Rivera S; Shahabi V; Paterson Y
Adv Appl Microbiol; 2009; 66():1-27. PubMed ID: 19203646
[TBL] [Abstract][Full Text] [Related]
31. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
32. Prospects for vaccine therapy for pancreatic cancer.
Gaudernack G
Best Pract Res Clin Gastroenterol; 2006 Apr; 20(2):299-314. PubMed ID: 16549329
[TBL] [Abstract][Full Text] [Related]
33. Recombinant viral vectors: cancer vaccines.
Harrop R; John J; Carroll MW
Adv Drug Deliv Rev; 2006 Oct; 58(8):931-47. PubMed ID: 17030074
[TBL] [Abstract][Full Text] [Related]
34. Technology evaluation: ALVAC-CEA/B7.1, Aventis Pasteur/Therion.
Ertl HC
Curr Opin Mol Ther; 2002 Dec; 4(6):601-5. PubMed ID: 12596363
[TBL] [Abstract][Full Text] [Related]
35. Priming anticancer active specific immunotherapy with dendritic cells.
Mocellin S
Curr Opin Investig Drugs; 2005 Jun; 6(6):576-81. PubMed ID: 15988908
[TBL] [Abstract][Full Text] [Related]
36. Technology Insight: vaccine therapy for prostate cancer.
Vieweg J; Dannull J
Nat Clin Pract Urol; 2005 Jan; 2(1):44-51. PubMed ID: 16474576
[TBL] [Abstract][Full Text] [Related]
37. [Dendrite cell-based cancer vaccines--clinical application].
Svane IM; Berntsen A; Trepiakas R; Pedersen AE
Ugeskr Laeger; 2006 Apr; 168(14):1415-20. PubMed ID: 16584668
[TBL] [Abstract][Full Text] [Related]
38. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses.
Conforti A; Peruzzi D; Giannetti P; Biondo A; Ciliberto G; La Monica N; Aurisicchio L
J Immunother; 2009 Sep; 32(7):744-54. PubMed ID: 19561534
[TBL] [Abstract][Full Text] [Related]
39. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
Xia D; Moyana T; Xiang J
Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
[TBL] [Abstract][Full Text] [Related]
40. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
